Sporecyte and Apacor Expand to the UK, EU: Bringing AI-Powered Mold Testing Solutions to Improve Environmental Standards

November 16, 2024 05:00 AM AEDT | By EIN Presswire
 Sporecyte and Apacor Expand to the UK, EU: Bringing AI-Powered Mold Testing Solutions to Improve Environmental Standards
Image source: EIN Presswire
OREM, UT, UNITED STATES, November 15, 2024 /EINPresswire.com/ -- Sporecyte, the industry leader in mold testing, along with Apacor, its trusted partner in the UK, is pleased to announce its expansion into the United Kingdom and the EU. This move marks a significant milestone in Sporecyte's mission to enhance air quality, environmental sustainability, and public health on a global scale.

Sporecyte is specialized in AI-powered mold spore and air particulate analysis. This expansion is critical for addressing air quality issues in residential homes, businesses, and public spaces.

"Expanding to the UK is an exciting development for Sporecyte," said Jason Callahan, General Manager at Sporecyte. "The UK is a hub of environmental innovation, and we are excited to contribute by offering data that can lead to meaningful improvements in air quality. Our technology will support public health efforts and enhance environmental policies across the region."

The UK and the EU both face significant challenges in air quality, particularly in urban areas. Sporecyte’s technology offers AI-powered analysis of airborne spores, pollen, and particulates, helping to identify dangerous levels of mold and other harmful organisms, and support timely interventions.

Through this expansion, Sporecyte aims to collaborate with local authorities, environmental agencies, and academic institutions to deliver accurate, timely air quality reports that can help shape the future of air quality management in the UK.

"We are pleased our Airtrap collection device and Sporecyte AI diagnosis is about offering proper detailed diagnosis of mold spores to customers in the UK. So homeowners and tenants can make actionable decisions. A timely addition to the market with Awaab’s law front and center in peoples minds," said Anthony Bellm, CEO of medical diagnostics company Apacor. "We are excited about the positive impact our technology will have on the lives of people across the UK."

Sporecyte’s expansion is part of a broader global strategy to tackle air quality challenges. With its innovative approach and proven track record, Sporecyte is well-positioned to support the UK and EU in its efforts to ensure cleaner air.

About Sporecyte:
Sporecyte has developed the world’s first AI-powered mold and air particulate report. We focus on providing home inspectors and industry professionals access to fast, accurate, and affordable mold and air quality testing.

About Techcyte:
Founded in 2013 in Orem, Utah, Techcyte is a world leader in AI-based digital diagnostics, including clinical and anatomic pathology. Techcyte’s AI and workflow platform uses AI to perform analysis of whole slide images, transforming diagnostics for human, animal, and environmental labs around the world.

Visit techcyte.com for more information.

Ben Cahoon
Techcyte, Inc.
+1 801-980-0414
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.